Christina M Sheerin1, Andrea T Kozak2, Andrew C Hale1, Bangalore K Ramesh3, C Richard Spates4. 1. Virginia Institute of Psychiatric and Behavioral Genetics, Virginia Commonwealth University, Richmond, VA, USA. 2. Department of Psychology, Oakland University, Rochester, MI, USA. 3. Western Michigan University School of Medicine, Kalamazoo, MI, USA. 4. Department of Psychology, Western Michigan University, Kalamazoo, MI, USA.
Abstract
BACKGROUND: The drug D-Cycloserine (DCS) has been used as an adjunct to increase the pace of symptom reductions during exposure therapy for anxiety disorders. This procedure has met with mixed results andmany questions remain. Aims: The findings from two investigations are reported here, highlighting important domains for furthering our understanding of DCS effects. METHOD: Study 1 (n = 16) treated social anxiety among a sample of emerging adults, and in addition to self-report utilized a behavioral measure of symptom improvement to evaluate outcomes. Study 2 (n = 16), utilizing a similar design, introduced an algorithm based post-session administration strategy following sessions where anxiety reductions were evident. Both investigations were double-blind, placebo controlled, randomized trials with participants diagnosed with social anxiety. Treatment was an exposure-based CBT-protocol adopted in other investigations that tested DCS. RESULTS: Findings of Study 1 yielded an interaction effect in favor of DCS for self-reported distress ratings (p=.02) and on a behavioral measure of anxiety (p=.01). Findings from Study 2 revealed a significant effect for self-reported subjective distress ratings (p=.002). CONCLUSIONS: Although limitations of small sample size constrain generalization and limit power, results illustrate some beneficial effects of DCS within the context of exposure-based intervention for social anxiety, yet are discussed in the context of statistical vs. clinical significance and the DCS literature as a whole. Present findings highlight the potential usefulness of a post-session administration strategy and the behavioral measure for future efforts with an eye towards preventing bias through more nuanced and powered studies.
RCT Entities:
BACKGROUND: The drug D-Cycloserine (DCS) has been used as an adjunct to increase the pace of symptom reductions during exposure therapy for anxiety disorders. This procedure has met with mixed results andmany questions remain. Aims: The findings from two investigations are reported here, highlighting important domains for furthering our understanding of DCS effects. METHOD: Study 1 (n = 16) treated social anxiety among a sample of emerging adults, and in addition to self-report utilized a behavioral measure of symptom improvement to evaluate outcomes. Study 2 (n = 16), utilizing a similar design, introduced an algorithm based post-session administration strategy following sessions where anxiety reductions were evident. Both investigations were double-blind, placebo controlled, randomized trials with participants diagnosed with social anxiety. Treatment was an exposure-based CBT-protocol adopted in other investigations that tested DCS. RESULTS: Findings of Study 1 yielded an interaction effect in favor of DCS for self-reported distress ratings (p=.02) and on a behavioral measure of anxiety (p=.01). Findings from Study 2 revealed a significant effect for self-reported subjective distress ratings (p=.002). CONCLUSIONS: Although limitations of small sample size constrain generalization and limit power, results illustrate some beneficial effects of DCS within the context of exposure-based intervention for social anxiety, yet are discussed in the context of statistical vs. clinical significance and the DCS literature as a whole. Present findings highlight the potential usefulness of a post-session administration strategy and the behavioral measure for future efforts with an eye towards preventing bias through more nuanced and powered studies.
Entities:
Keywords:
combined treatment; d-cycloserine; exposure therapy; social anxiety
Authors: Kerry J Ressler; Barbara O Rothbaum; Libby Tannenbaum; Page Anderson; Ken Graap; Elana Zimand; Larry Hodges; Michael Davis Journal: Arch Gen Psychiatry Date: 2004-11
Authors: Rianne A de Kleine; Gert-Jan Hendriks; Wendy J C Kusters; Theo G Broekman; Agnes van Minnen Journal: Biol Psychiatry Date: 2012-04-04 Impact factor: 13.382
Authors: Jasper A J Smits; David Rosenfield; Michael W Otto; Mark B Powers; Stefan G Hofmann; Michael J Telch; Mark H Pollack; Candyce D Tart Journal: Biol Psychiatry Date: 2013-01-16 Impact factor: 13.382
Authors: Jasper A J Smits; David Rosenfield; Michael W Otto; Luana Marques; Michelle L Davis; Alicia E Meuret; Naomi M Simon; Mark H Pollack; Stefan G Hofmann Journal: J Psychiatr Res Date: 2013-07-16 Impact factor: 4.791
Authors: Jasper A J Smits; Stefan G Hofmann; David Rosenfield; Lindsey B DeBoer; Paul T Costa; Naomi M Simon; Conall O'Cleirigh; Alicia E Meuret; Luana Marques; Michael W Otto; Mark H Pollack Journal: J Consult Clin Psychol Date: 2013-08-12
Authors: Stefan G Hofmann; Alicia E Meuret; Jasper A J Smits; Naomi M Simon; Mark H Pollack; Katherine Eisenmenger; Michael Shiekh; Michael W Otto Journal: Arch Gen Psychiatry Date: 2006-03